A highly efficient and sensitive method for detecting arsenic content in blood
Through the reaction of porous cobalt oxide nanosheets with thiol monomer and the combination of color developer powder, combined with magnetic nanoferrous tetraoxide and dopamine modification, the problem of arsenic detection in blood is easily disturbed and nanosheet agglomerated, and the detection is improved sensitivity and accuracy.
Patent Information
- Application Number
- CN202410652417.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-24
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-05-24
AI Technical Summary
The existing arsenic detection methods in the blood are susceptible to interference from other metal ions, have low detection efficiency and nanosheets are prone to agglomeration, affecting the detection accuracy.
The reaction of porous cobalt oxide nanosheets with thiol monomers consumes the hydroxyl structure, combines the color developer powder and magnetic nano iron tetroxide to form a composite detector, shorten the distance between the nanosheets and the color developer, and enhances the arsenic Adsorption properties and enhance the binding force of arsenic through dopamine modification to avoid agglomeration.
It improves the detection sensitivity and accuracy of arsenic in the blood, reduces other signal interference, enhances the adsorption capacity of arsenic, and avoids the reduction in detection efficiency caused by nanosheet agglomeration.
Smart Images

Figure BDA0004856806880000141
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of blood arsenic chemical analysis, in particular to a high-efficiency and sensitive detection method for arsenic content in blood. Background Art
[0002] Arsenic is a toxic and widely distributed element. It exists in the form of various inorganic and organic substances, mainly in the form of trivalent arsenic and pentavalent arsenic in food and drinking water. Trivalent arsenic is more toxic. Long-term contact with arsenic in food and drinking water will cause arsenic to seep into the human blood, increasing the risk of cancer of the skin, lungs, bladder and kidneys. This type of toxin is difficult to be excreted from the body. The main detection methods for arsenic content in the blood include atomic absorption spectrometry, atomic emission spectrometry, inductively coupled plasma mass spectrometry and electrochemical analysis. Arsenic can combine with the sulfhydryl and hydroxyl groups in the molecular structure of enzyme proteins in the body, making the enzyme inactive and seriously endangering the nervous system, circulatory system and digestive system.
[0003] The current detection method for arsenic in the blood has a single measurement mode and is easily interfered by other metal ions in the blood, affecting the accuracy of the arsenic detection results in the blood; cobalt oxyhydroxide nanosheets can capture arsenic in the blood and complete the detection of arsenic in the blood, but the hydroxyl groups on the surface of cobalt oxyhydroxide nanosheets are adsorbable to other metal ions in the blood, resulting in low detection efficiency, and cobalt oxyhydroxide nanosheets are easy to agglomerate in blood samples, limiting the use of cobalt oxyhydroxide nanosheets for detecting arsenic content in the blood. Summary of the invention
[0004] The purpose of the present invention is to provide a highly efficient and sensitive detection method for arsenic content in blood: porous cobalt oxyhydroxy nanosheets react with thiol monomers to consume the hydroxyl structure of the porous cobalt oxyhydroxy nanosheets, avoid the porous cobalt oxyhydroxy nanosheets from adsorbing other metal ions in the blood, occupy the binding sites of the porous cobalt oxyhydroxy nanosheets, and reduce the adsorption performance of arsenic; color developer powder is filled into the modified porous cobalt oxyhydroxy nanosheets to shorten the distance between the modified cobalt oxyhydroxy nanosheets and the color developer powder, so that the detection is more efficient and sensitive, and the interference of other signals can be reduced, thereby improving the efficient detection efficiency of arsenic in the blood; dopamine is modified with nano ferroferric oxide, and then mixed with composite porous cobalt oxyhydroxy nanosheets, the amino groups contained in the nanosheets can also form arsenic-nitrogen bonds with arsenic in the blood, thereby enhancing the binding force to the arsenic element and improving the adsorption capacity to arsenic, and the composite porous cobalt oxyhydroxy nanosheets are loaded on the surface of magnetic nano ferroferric oxide to avoid the agglomeration of the composite porous cobalt oxyhydroxy nanosheets, resulting in failure or reduction of arsenic detection efficiency.
[0005] The technical problem to be solved by the present invention is as follows: the current detection method for arsenic in blood has a single measurement mode and is easily interfered by other metal ions in the blood, thus affecting the accuracy of the detection result of arsenic in the blood; cobalt oxyhydroxide nanosheets can capture arsenic in the blood and complete the detection of arsenic in the blood, but the hydroxyl groups contained on the surface of the cobalt oxyhydroxide nanosheets are adsorbent to other metal ions in the blood, resulting in low detection efficiency, and the cobalt oxyhydroxide nanosheets are easily aggregated in blood samples, which limits the use of the cobalt oxyhydroxide nanosheets for detecting the arsenic content in the blood.
[0006] To achieve the above object, the present invention provides the following technical solutions:
[0007] A highly efficient and sensitive method for detecting arsenic content in blood comprises the following steps:
[0008] S1. Mix the venous blood sample with the digestion reagent, stir, place on a heating plate for digestion, cool to room temperature, add deionized water, and obtain a blood sample to be tested.
[0009] The venous blood sample is mixed with a digestion reagent and digested at 90°C. The organic matter in the venous blood sample undergoes a chemical reaction, causing the organic and inorganic matter in the venous blood sample to decompose, releasing the element arsenic to be tested, and removing other components that may interfere with the detection.
[0010] Furthermore, the volume ratio of the venous blood sample, the digestion reagent, and the deionized water is 2-3:8-12:40-60.
[0011] S2. Mix the arsenic detector with deionized water and stir to obtain a nanohybrid solution.
[0012] S3. Add the nano-hybrid solution to the blood sample to be tested, stir to obtain a mixed solution, place the mixed solution on a multifunctional detection platform, record the absorbance and fluorescence intensity, and obtain the arsenic content A based on the linear equation relationship between the fluorescence intensity and absorbance and the arsenic concentration.
[0013] S4. After filtering the mixed solution, place it in an analytical solution for analysis, take the supernatant and detect the arsenic content B by inductively coupled plasma mass spectrometry, and take the average value of the arsenic content A and the arsenic content B, which is the arsenic content in the blood.
[0014] Furthermore, the digestion reagent is prepared by mixing a nitric acid solution and a hydrogen peroxide solution in a volume ratio of 6-10:1-3.
[0015] Furthermore, the concentration of nitric acid is 0.5-0.7 mol / L, and the concentration of hydrogen peroxide solution is 0.29-0.32 mol / L.
[0016] More preferably, the concentration of nitric acid is 0.6 mol / L, and the concentration of hydrogen peroxide solution is 0.3 mol / L.
[0017] Furthermore, the wavelength of the multifunctional detection platform in UV mode is 460-470nm, the wavelength in fluorescence mode is 480-500nm, and the emission wavelength is 520-530nm.
[0018] Further preferably, the wavelength of the multifunctional detection platform in ultraviolet mode is 465 nm, the wavelength in fluorescence mode is 490 nm, and the emission wave is 527 nm.
[0019] Furthermore, the linear equation of fluorescence intensity and arsenic concentration is fluorescence intensity = 21416 × arsenic concentration + 6185.6.
[0020] Furthermore, the linear equation of absorbance and arsenic concentration was 0.0039×arsenic concentration-0.0017.
[0021] Furthermore, the analytical solution is prepared by mixing a sodium thiosulfate solution and a potassium iodide solution in a volume ratio of 8-12:5-8.
[0022] Furthermore, the concentration of the sodium thiosulfate solution is 0.1-0.3 mol / L, and the concentration of the potassium iodide solution is 0.03-0.05 mol / L.
[0023] More preferably, the concentration of the sodium thiosulfate solution is 0.2 mol / L, and the concentration of the potassium iodide solution is 0.04 mol / L.
[0024] Furthermore, the arsenic detector is prepared by modifying nano-ferroferric oxide with dopamine and then mixing it with composite porous cobalt oxyhydroxide nanosheets; the preparation is specifically carried out by the following steps:
[0025] Tris(hydroxymethyl)aminomethane was added to deionized water and stirred evenly. A hydrochloric acid solution with a mass fraction of 36% was added to adjust the pH value to 8.5, and the volume was fixed to obtain a Tris-HCl buffer. Nano-ferroferric oxide was added to the Tris-HCl buffer and stirred evenly. Dopamine was added, ultrasonicated for 5 minutes, stirred at 25°C for 4 hours, composite porous cobalt hydroxide oxide nanosheets were added, stirred, and allowed to stand for 10 minutes. The mixture was filtered, washed with deionized water for 3 times, and dried at 80°C for 8 minutes to obtain an arsenic detector.
[0026] Among them, dopamine can self-polymerize in Tris-HCl buffer and deposit on the surface of nano-ferroferric oxide, so that the nano-ferroferric oxide has high adhesion and can adhere to the composite porous cobalt oxyhydroxide nanosheets, so that the composite porous cobalt oxyhydroxide nanosheets adhere to the surface of the nano-ferroferric oxide, avoiding the agglomeration of the composite porous cobalt oxyhydroxide nanosheets and causing the arsenic detection efficiency to fail or decrease.
[0027] Furthermore, the modified cobalt hydroxide oxide nanosheets contained in the prepared arsenic detector have high oxidation activity and can oxidize p-phenylenediamine to form p-phenylenediamine oxide, so that the p-phenylenediamine oxide combines with acridine orange in the arsenic detector to exhibit high absorbance and low fluorescence characteristics. By combining with blood arsenic, arsenic can combine with the thiol groups on the surface of the modified cobalt hydroxide oxide nanosheets contained in the arsenic detector, thereby inhibiting the oxidation activity of the modified cobalt hydroxide oxide nanosheets, resulting in low absorbance and high fluorescence characteristics. By utilizing this change, through the linear relationship between fluorescence intensity and absorbance and arsenic concentration, it can be used for sensitive and directional detection of arsenic, thereby improving the accuracy and flexibility of blood arsenic content detection.
[0028] Furthermore, the dosage ratio of nano-ferroferric oxide, Tris-HCl buffer, dopamine, and composite porous cobalt oxyhydroxy nanosheets is 2-3 g:45-55 mL:0.6-1 g:0.1-0.3 g.
[0029] Further, nano-ferroferric oxide is prepared by the following steps:
[0030] Ferric chloride hexahydrate and ferrous chloride tetrahydrate are added to deionized water, stirred at 85°C for 30 minutes, and then a 30% by volume ammonia solution is added, stirred and reacted for 30 minutes, cooled to warm, filtered, washed with deionized water 3 times, washed with ethanol 2 times, and dried in an oven at 80°C for 10 minutes to obtain nano-ferrosoferric oxide.
[0031] Among them, ammonia water provides hydroxide ions, which combine with iron ions in ferric chloride hexahydrate and ferrous ions in ferrous chloride tetrahydrate to form an iron-based complex. After hydrothermal treatment, the iron-based complex is dehydrated to form ferroferric oxide crystals, and the crystals nucleate and grow to form magnetic nano-ferroferric oxide.
[0032] Furthermore, the dosage ratio of ferric chloride hexahydrate, ferrous chloride tetrahydrate and ammonia solution is 5.1-5.5 g: 2-2.4 g: 4-8 mL.
[0033] Furthermore, the composite porous cobalt oxyhydroxide nanosheets are prepared by mixing developer powder with an organic solvent, filling the mixture into modified porous cobalt oxyhydroxide nanosheets, and then heat treating, washing, drying and grinding.
[0034] Furthermore, the developer powder is prepared by mixing acridine orange and o-phenylenediamine in a mass ratio of 10-14:3-7.
[0035] Furthermore, the heat treatment temperature is 78-85°C, and the heat treatment time is 30-50min.
[0036] More preferably, the heat treatment temperature is 80° C. and the heat treatment time is 40 min.
[0037] Furthermore, the organic solvent is selected from ethanol.
[0038] Furthermore, the composite porous cobalt oxyhydroxide nanosheet is prepared by the following steps:
[0039] The developer powder was added to the organic solvent ethanol, stirred at 30°C until the powder was completely dissolved, the modified porous cobalt oxyhydroxy nanosheets were added, ultrasonically treated for 10 minutes, allowed to stand for 5 minutes, heated to 80°C, heat treated for 40 minutes until the organic solvent evaporated, washed three times with deionized water, dried in an oven at 70°C for 10 minutes, and ground in a grinder to obtain composite porous cobalt oxyhydroxy nanosheets.
[0040] The developer powder is dissolved in the organic solvent ethanol to form a fluid solution. The porous structure of the modified porous cobalt hydroxy oxide nanosheets has excellent adsorption properties. The fluid solution is adsorbed on the surface and pores of the modified porous cobalt hydroxy oxide nanosheets. After heat treatment at 80°C, the organic solvent is volatilized, and the developer powder is embedded in the surface and pores of the porous cobalt hydroxy oxide nanosheets. The modified cobalt hydroxy oxide nanosheets and the developer powder are then compounded to shorten the distance between the modified cobalt hydroxy oxide nanosheets and the developer powder, making the detection more efficient and sensitive.
[0041] Furthermore, the mass ratio of the developer powder, the organic solvent, and the modified porous cobalt oxyhydroxide nanosheets is 16-19 g:45-55 mL:0.3-0.7 g.
[0042] Furthermore, the modified porous cobalt oxyhydroxide nanosheets are prepared by reacting the porous cobalt oxyhydroxide nanosheets with a mercapto monomer.
[0043] Furthermore, the mercapto monomer is selected from any one of 2,3-dimercaptosuccinic acid and ethanedithiol.
[0044] Furthermore, the porous cobalt oxyhydroxide nanosheet has a particle size of 400-500 nm and a pore size of 50-80 nm.
[0045] Furthermore, the modified porous cobalt oxyhydroxide nanosheets are prepared by the following steps:
[0046] A1. A 1.2 mol / L sodium hydroxide solution was mixed with a 10 mol / L cobalt chloride solution, and ultrasonically treated for 1 min. A 0.9 mol / L sodium hypochlorite solution, methanol and a 36% ammonia solution were added. After stirring at 100°C for 12 h, the mixture was ultrasonically treated for 10 min. The mixture was centrifuged at 1000 r / min for 10 min, and the precipitate was taken out. The precipitate was washed three times with deionized water and dried in an oven at 60°C to obtain porous cobalt oxyhydroxy nanosheets.
[0047] Among them, cobalt ions in the cobalt chloride solution can combine with hydroxide ions in the sodium hydroxide solution to form a cobalt hydroxide suspension. After oxidation with sodium hypochlorite, the cobalt hydroxide is oxidized to form cobalt hydroxide oxide nanosheets. In the hydrothermal oxidation process at 100°C, methanol and ammonia solutions are thermally decomposed to release gas, thereby forming a large number of pores on the surface of the cobalt hydroxide oxide nanosheets, improving the adsorption capacity and adsorption sites of the cobalt hydroxide oxide nanosheets, increasing the loading amount of the color developer powder, and increasing the detection efficiency of arsenic.
[0048] Furthermore, the volume ratio of sodium hydroxide solution, cobalt chloride solution, sodium hypochlorite solution, methanol and ammonia solution is 0.5-1.5:3-5:0.02-0.07:0.02-0.04:0.01-0.03.
[0049] A2. Add porous cobalt hydroxide oxide nanosheets to ethanol, stir evenly, add thiol monomer 2,3-dimercaptosuccinic acid and 36% sulfuric acid solution by mass, stir and react at 40°C for 3 hours, cool to room temperature, wash with ethanol twice, wash with deionized water until the pH of the washing solution is neutral, and dry in an oven at 60°C for 10 minutes to obtain modified porous cobalt hydroxide oxide nanosheets.
[0050] Among them, sulfuric acid acts as a catalyst, so that the hydroxyl groups contained in the surface and pores of the porous cobalt oxyhydroxide nanosheets can react with the carboxyl groups of the thiol monomer 2,3-dimercaptosuccinic acid, so that the thiol monomer 2,3-dimercaptosuccinic acid is grafted on the surface and pores of the porous cobalt oxyhydroxide nanosheets, consuming the hydroxyl structure of the porous cobalt oxyhydroxide nanosheets, avoiding the adsorption of other metal ions in the blood by the porous cobalt oxyhydroxide nanosheets, occupying the binding sites of the porous cobalt oxyhydroxide nanosheets, and resulting in reduced adsorption performance for arsenic.
[0051] Furthermore, the amount ratio of the porous cobalt oxyhydroxide nanosheets, ethanol, mercapto monomer, and sulfuric acid solution is 0.3-0.7 g: 45-55 mL: 1-3 mL: 0.2-0.4 g.
[0052] Furthermore, compared with the prior art, the present invention has the following beneficial effects:
[0053] (1) In the technical solution of the present invention, the venous blood sample is digested with a digestion reagent, and the organic and inorganic substances in the organic matter in the venous blood sample are decomposed to release the element arsenic to be detected, which makes it easy to detect arsenic in the blood and improves the detection sensitivity. In addition, the venous blood sample is digested to remove other components that may interfere with the detection.
[0054] (2) In the technical scheme of the present invention, a large number of pores are formed on the surface of the cobalt oxyhydroxide nanosheet, which increases the adsorption capacity and adsorption sites of the cobalt oxyhydroxide nanosheet, increases the loading amount of the developer powder, and increases the detection efficiency of arsenic; the thiol monomer 2,3-dimercaptosuccinic acid is grafted on the surface and pores of the porous cobalt oxyhydroxide nanosheet, consumes the hydroxyl structure of the porous cobalt oxyhydroxide nanosheet, avoids the adsorption of other metal ions in the blood by the porous cobalt oxyhydroxide nanosheet, occupies the binding sites of the porous cobalt oxyhydroxide nanosheet, and leads to a decrease in the adsorption performance of arsenic. The introduced thiol monomer 2,3-dimercaptosuccinic acid, the thiol contained in it can be combined with arsenic in the blood through chemical bonds, realizes directional binding of blood arsenic, and improves the adsorption of blood arsenic element. In addition, the thiol monomer 2,3-dimercaptosuccinic acid provides more thiol groups, thereby increasing the adsorption capacity of blood arsenic and improving the detection efficiency.
[0055] (3) In the technical solution of the present invention, a color developer powder formed by mixing acridine orange and o-phenylenediamine is embedded in the surface and pores of the porous cobalt oxyhydroxy nanosheets, and the modified cobalt oxyhydroxy nanosheets and the color developer powder are compounded to shorten the distance between the modified cobalt oxyhydroxy nanosheets and the color developer powder, thereby making the detection more efficient and sensitive, and reducing the interference of other signals, thereby improving the efficiency of the detection of arsenic in the blood.
[0056] (4) In the technical scheme of the present invention, the composite porous cobalt oxyhydroxide nanosheets are loaded on the surface of the magnetic nano-ferroferric oxide to avoid the agglomeration of the composite porous cobalt oxyhydroxide nanosheets which leads to the failure or reduction of the arsenic detection efficiency. The nano-ferroferric oxide can make the porous cobalt oxyhydroxide nanosheets have magnetic separation ability, and the nanosheets adsorbed with arsenic can be conveniently separated and enriched by an external magnetic field. In addition, the amino group contained in the polydopamine on the surface of the magnetic nano-ferroferric oxide can also form an arsenic-nitrogen bond with arsenic in the blood, thereby enhancing the binding force to the arsenic element and improving the adsorption capacity for arsenic.
[0057] (5) In the technical scheme of the present invention, the modified cobalt oxyhydroxy nanosheets contained in the prepared arsenic detector have high oxidation activity and can oxidize p-phenylenediamine to form p-phenylenediamine oxide, so that the p-phenylenediamine oxide combines with acridine orange in the arsenic detector to exhibit high absorbance and low fluorescence characteristics. By combining with blood arsenic, arsenic can combine with the thiol groups on the surface of the modified cobalt oxyhydroxy nanosheets contained in the arsenic detector, thereby inhibiting the oxidation activity of the modified cobalt oxyhydroxy nanosheets, resulting in low absorbance and high fluorescence characteristics. By utilizing this change, through the linear relationship between fluorescence intensity and absorbance and arsenic concentration, it can be used for sensitive and directional detection of arsenic, thereby improving the accuracy and flexibility of blood arsenic content detection. DETAILED DESCRIPTION
[0058] The technical solutions in the embodiments of the present invention are described clearly and completely. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0059] The raw materials used in the embodiments of the present invention are as follows: tris(hydroxymethylaminomethane) (Aladdin Reagent, Shanghai Co., Ltd.); nitric acid solution (concentration of 0.6 mol / L, premium grade); hydrogen peroxide solution (premium grade, concentration of 0.3 mol / L); dopamine (analytical grade, manufacturer: Tianjin Komiou Chemical Reagent Co., Ltd.); ferric chloride hexahydrate, ferrous chloride tetrahydrate (analytical grade, purchased from Sinopharm Group Reagent Co., Ltd.); acridine orange (model 10127-02-3, purity of 80%)); o-phenylenediamine (manufacturer: Shanghai Adamas Reagent Co., Ltd., purity of 99%); 2,3-dimercaptosuccinic acid (manufacturer: Tianjin Zhiyuan Chemical Reagent Co., Ltd., analytical grade); sodium hypochlorite (active chlorine, purity of 8.5%); cobalt chloride (purity of 99.7, purchased from Shanghai McLean Biochemical Reagent Co., Ltd.); cobalt chloride solution (manufacturer: Tianjin Zhiyuan Chemical Reagent Co., Ltd., analytical grade).
[0060] Example 1
[0061] The composite porous cobalt oxyhydroxide nanosheets are prepared by the following steps:
[0062] A1. 1 mL of 1.2 mol / L sodium hydroxide solution was mixed with 4 mL of 10 mol / L cobalt chloride solution, and ultrasonically treated for 1 min. 0.05 mL of 0.9 mol / L sodium hypochlorite solution, 0.03 mL of methanol and 0.02 mL of 36% ammonia solution were added. After stirring at 100° C. for 12 h, ultrasonic treatment was performed for 10 min. The mixture was centrifuged at 1000 r / min for 10 min, and the precipitate was taken out. The precipitate was washed three times with deionized water and dried in an oven at 60° C. to obtain porous cobalt oxyhydroxy nanosheets.
[0063] A2. Add 0.5 g of porous cobalt oxyhydroxy nanosheets to 50 mL of ethanol, stir evenly, add 2 mL of thiol monomer 2,3-dimercaptosuccinic acid and 0.3 g of 36% sulfuric acid solution, stir and react at 40°C for 3 h, cool to room temperature, wash twice with ethanol, wash with deionized water until the pH of the washing solution is neutral, and dry in an oven at 60°C for 10 min to obtain modified porous cobalt oxyhydroxy nanosheets.
[0064] A3. Mix 12g of acridine orange and 5g of o-phenylenediamine, add to 50mL of ethanol, stir at 30°C until the powder is completely dissolved, add 0.5g of modified porous cobalt oxyhydroxy nanosheets, ultrasonically treat for 10min, let stand for 5min, heat to 80°C, heat treat for 40min until the organic solvent evaporates, wash three times with deionized water, dry in an oven at 70°C for 10min, and grind in a grinder to obtain composite porous cobalt oxyhydroxy nanosheets.
[0065] Comparative Example 1
[0066] The difference between this comparative example and Example 1 is that the modified porous cobalt oxyhydroxide nanosheets are replaced by porous cobalt oxyhydroxide nanosheets, and the remaining steps and raw materials are the same as Example 1.
[0067] Comparative Example 2
[0068] The difference between this comparative example and Example 1 is that the modified porous cobalt oxyhydroxide nanosheets are replaced by cobalt oxyhydroxide nanosheets, and the remaining steps and raw materials are the same as those of Example 1.
[0069] Example 2
[0070] The arsenic detection agent is specifically prepared by the following steps:
[0071] B1. Add 5.3 g of ferric chloride hexahydrate and 2.2 g of ferrous chloride tetrahydrate to 100 mL of deionized water, stir at 85°C for 30 min, then add 6 mL of 30% ammonia solution, stir and react for 30 min, cool to warm, filter, wash 3 times with deionized water, wash 2 times with ethanol, and dry in an oven at 80°C for 10 min to obtain nano-ferrosoferric oxide.
[0072] B2. Add 0.24g of tris(hydroxymethyl)aminomethane to 90mL of deionized water, stir evenly, add 2.5mL of 36% hydrochloric acid solution to adjust the pH to 8.5, and then adjust the volume to 100mL to obtain Tris-HCl buffer, add 2.5g of nano-ferroferric oxide to 50mL of Tris-HCl buffer, stir evenly, add 0.8g of dopamine, ultrasonicate for 5min, stir at 25°C for 4h, add 0.2g of composite porous cobalt hydroxide oxide nanosheets, stir, let stand for 10min, filter, wash with deionized water 3 times, and dry at 80°C for 8min to obtain an arsenic detector.
[0073] Comparative Example 3
[0074] The difference between this comparative example and Example 2 is that the composite porous cobalt oxyhydroxide nanosheets are replaced with the material prepared in Comparative Example 1, and the remaining steps are synchronized with Example 2.
[0075] Comparative Example 4
[0076] The difference between this comparative example and Example 2 is that the composite porous cobalt oxyhydroxide nanosheets are replaced with the material prepared in Comparative Example 2, and the remaining steps are synchronized with Example 2.
[0077] Comparative Example 5
[0078] The difference between this comparative example and Example 2 is that nano-ferroferric oxide is not added, and the remaining steps and raw materials are the same as those of Example 2.
[0079] Comparative Example 6
[0080] The difference between this comparative example and Example 2 is that the nano-ferroferric oxide is not modified with dopamine, and the remaining steps and raw materials are the same as those in Example 2.
[0081] Example 3
[0082] A highly efficient and sensitive method for detecting arsenic content in blood comprises the following steps:
[0083] S1. Mix 6 mL of 0.6 mol / L nitric acid solution with 1 mL of 0.3 mol / L hydrogen peroxide solution to obtain a digestion reagent. Place 2.5 mL of venous blood sample in a digestion tank, add 7 mL of digestion reagent, stir, place on a heating plate, digest at 90 ° C for 3 hours, cool to room temperature, add 50 mL of deionized water for dilution, and obtain a blood sample to be tested.
[0084] S2. Mix 0.5 g of arsenic detector with 15 mL of deionized water and stir to obtain a nanohybrid solution.
[0085] S3. Add the nano-hybrid solution to the blood sample to be tested and stir to obtain a mixed solution. Place the mixed solution on a multifunctional detection platform, record the absorbance and fluorescence intensity under the conditions of a wavelength of 465 nm in ultraviolet mode, a wavelength of 490 nm in fluorescence mode, and an emission wavelength of 527 nm, and obtain the arsenic content A based on the linear equation relationship between the fluorescence intensity and the absorbance and the arsenic concentration, wherein the linear equation of the fluorescence intensity and the arsenic concentration is fluorescence intensity = 21416 × arsenic concentration + 6185.6, and the linear equation of the absorbance and the arsenic concentration is 0.0039 × arsenic concentration - 0.0017.
[0086] S4. Mix 8 mL of 0.2 mol / L sodium thiosulfate solution and 5 mL of 0.04 mol / L potassium iodide solution to obtain a analytical solution. After magnetic separation, the mixed solution in step S3 is placed in 13 mL of analytical solution for analysis. The supernatant is taken for inductively coupled plasma mass spectrometry to detect the arsenic content B. The average value of the arsenic content A and the arsenic content B is taken, which is the arsenic content in the blood.
[0087] Example 4
[0088] A highly efficient and sensitive method for detecting arsenic content in blood comprises the following steps:
[0089] S1. Mix 8 mL of 0.6 mol / L nitric acid solution with 2 mL of 0.3 mol / L hydrogen peroxide solution to obtain a digestion reagent. Place 2.5 mL of venous blood sample in a digestion tank, add 10 mL of digestion reagent, stir, place on a heating plate, digest at 90 ° C for 3 hours, cool to room temperature, add 50 mL of deionized water for dilution, and obtain a blood sample to be tested.
[0090] S2. Mix 0.75 g of arsenic detector with 20 mL of deionized water and stir to obtain a nanohybrid solution.
[0091] S3. Add the nano-hybrid solution to the blood sample to be tested and stir to obtain a mixed solution. Place the mixed solution on a multifunctional detection platform, record the absorbance and fluorescence intensity under the conditions of a wavelength of 465 nm in ultraviolet mode, a wavelength of 490 nm in fluorescence mode, and an emission wavelength of 527 nm, and obtain the arsenic content A based on the linear equation relationship between the fluorescence intensity and the absorbance and the arsenic concentration, wherein the linear equation of the fluorescence intensity and the arsenic concentration is fluorescence intensity = 21416 × arsenic concentration + 6185.6, and the linear equation of the absorbance and the arsenic concentration is 0.0039 × arsenic concentration - 0.0017.
[0092] S4. Mix 10 mL of 0.2 mol / L sodium thiosulfate solution and 6.5 mL of 0.04 mol / L potassium iodide solution to obtain a analytical solution. After magnetic separation, the mixed solution in step S3 is placed in 16.5 mL of analytical solution for analysis. The supernatant is taken for inductively coupled plasma mass spectrometry to detect the arsenic content B. The average value of the arsenic content A and the arsenic content B is taken, which is the arsenic content in the blood.
[0093] Example 5
[0094] A highly efficient and sensitive method for detecting arsenic content in blood comprises the following steps:
[0095] S1. Mix 10 mL of 0.6 mol / L nitric acid solution with 3 mL of 0.3 mol / L hydrogen peroxide solution to obtain a digestion reagent. Place 3 mL of venous blood sample in a digestion tank, add 13 mL of digestion reagent, stir, place on a heating plate, digest at 90 ° C for 3 hours, cool to room temperature, add 55 mL of deionized water for dilution, and obtain a blood sample to be tested.
[0096] S2. Mix 1 g of arsenic detector with 25 mL of deionized water and stir to obtain a nanohybrid solution.
[0097] S3. Add the nano-hybrid solution to the blood sample to be tested and stir to obtain a mixed solution. Place the mixed solution on a multifunctional detection platform, record the absorbance and fluorescence intensity under the conditions of a wavelength of 465 nm in ultraviolet mode, a wavelength of 490 nm in fluorescence mode, and an emission wavelength of 527 nm, and obtain the arsenic content A based on the linear equation relationship between the fluorescence intensity and the absorbance and the arsenic concentration, wherein the linear equation of the fluorescence intensity and the arsenic concentration is fluorescence intensity = 21416 × arsenic concentration + 6185.6, and the linear equation of the absorbance and the arsenic concentration is 0.0039 × arsenic concentration - 0.0017.
[0098] S4. Mix 12 mL of 0.2 mol / L sodium thiosulfate solution and 8 mL of 0.04 mol / L potassium iodide solution to obtain a analytical solution. After magnetic separation, the mixed solution in step S3 is placed in 20 mL of analytical solution for analysis. The supernatant is taken for inductively coupled plasma mass spectrometry to detect the arsenic content B. The average value of the arsenic content A and the arsenic content B is taken, which is the arsenic content in the blood.
[0099] Comparative Example 7
[0100] The difference between this comparative example and Example 4 is that the arsenic detection agent is replaced by the substance prepared in Comparative Example 3, and the remaining steps are synchronized with Example 4.
[0101] Comparative Example 8
[0102] The difference between this comparative example and Example 4 is that the arsenic detection agent is replaced by the substance prepared in Comparative Example 4, and the remaining steps are synchronized with Example 4.
[0103] Comparative Example 9
[0104] The difference between this comparative example and Example 4 is that the arsenic detection agent is replaced by the substance prepared in Comparative Example 5, and the remaining steps are synchronized with Example 4.
[0105] Comparative Example 10
[0106] The difference between this comparative example and Example 4 is that the arsenic detection agent is replaced by the substance prepared in Comparative Example 6, and the remaining steps are synchronized with Example 4.
[0107] Now, for Examples 3-5 and Comparative Examples 7-10, an efficient and sensitive method for detecting arsenic content in blood is tested;
[0108] The mixed solution prepared above was placed on a multifunctional detection platform, and the absorbance and fluorescence intensity were recorded under the conditions of a wavelength of 465 nm in ultraviolet mode, a wavelength of 490 nm in fluorescence mode, and an emission wave of 527 nm. The arsenic content A was obtained based on the linear equation relationship between the fluorescence intensity and the absorbance and the arsenic concentration, wherein the linear equation of the fluorescence intensity and the arsenic concentration was fluorescence intensity = 21416 × arsenic concentration + 6185.6, and the linear equation of the absorbance and the arsenic concentration was 0.0039 × arsenic concentration - 0.0017.
[0109] 10 mL of a 0.2 mol / L sodium thiosulfate solution and 6.5 mL of a 0.04 mol / L potassium iodide solution were mixed to form a analytical solution. The mixed solution prepared above was filtered and then placed in 16.5 mL of analytical solution for analysis. The supernatant was taken for inductively coupled plasma mass spectrometry to detect the arsenic content B. The average of the arsenic content A and the arsenic content B was taken, and the average arsenic content was recorded. The blood arsenic level of a normal person is 0.13-8.54 μmol / L. The present invention selects a blood arsenic content of 6.51 μmol / L. The test results are shown in Table 1 below:
[0110] Table 1
[0111]
[0112] It can be seen from the data in Table 1 that in Comparative Example 7, the modified porous cobalt oxyhydroxy nanosheets are replaced with the arsenic detection agent prepared by the porous cobalt oxyhydroxy nanosheets for the detection of blood arsenic, and its fluorescence intensity and absorbance are reduced compared with those of Examples 1-3. This may be because 2,3-dimercaptosuccinic acid is grafted on the surface and pores of the porous cobalt oxyhydroxy nanosheets, consuming the hydroxyl structure of the porous cobalt oxyhydroxy nanosheets, avoiding the adsorption of other metal ions in the blood by the porous cobalt oxyhydroxy nanosheets, occupying the binding sites of the porous cobalt oxyhydroxy nanosheets, and causing the adsorption performance of arsenic to be reduced; Comparative Example 8 is an arsenic detection agent prepared by replacing the modified porous cobalt oxyhydroxy nanosheets with cobalt oxyhydroxy nanosheets for the detection of blood arsenic, and its fluorescence intensity and absorbance are reduced compared with those of Examples 1-3. This may be because the modified cobalt oxyhydroxy nanosheets and the developer powder are compounded , shortening the distance between the modified cobalt hydroxide oxide nanosheets and the developer powder, making the detection more efficient and sensitive, and reducing the interference of other signals; in comparative example 9, an arsenic detection agent prepared without adding nano-iron tetroxide is used for the detection of blood arsenic, and its fluorescence intensity and absorbance are decreased compared with those of examples 1-3. This may be because the composite porous cobalt hydroxide oxide nanosheets are loaded on the surface of magnetic nano-iron tetroxide to avoid the agglomeration of the composite porous cobalt hydroxide oxide nanosheets, resulting in failure or reduction of arsenic detection efficiency; comparative example 10 is an arsenic detection agent prepared without dopamine modification of nano-iron tetroxide, and is used for the detection of blood arsenic. Its fluorescence intensity and absorbance are decreased compared with those of examples 1-3. This may be because the amino group contained in the polydopamine on the surface of the ferroferric oxide can also form arsenic-nitrogen bonds with arsenic in the blood, thereby enhancing the binding force to the arsenic element and improving the adsorption capacity for arsenic.
[0113] The data in Table 1 illustrate that Example 3-5 is an efficient and sensitive detection method for arsenic content in blood, which can reduce the interference of other signals, and is more flexible and accurate in practical applications. The venous blood sample is mixed with a digestion reagent, stirred, placed on a heating plate for digestion, cooled to room temperature, and deionized water is added to obtain a blood sample to be detected; the arsenic detector is mixed with deionized water, stirred to obtain a nano-hybrid solution; the nano-hybrid solution is added to the blood sample to be detected, stirred to obtain a mixed solution, the mixed solution is placed on a multifunctional detection platform, the absorbance and fluorescence intensity are recorded, and the arsenic content A is obtained according to the linear equation relationship between the fluorescence intensity and the absorbance and the arsenic concentration; the mixed solution is subjected to magnetic separation, placed in the mixed solution for analysis, and the supernatant is taken for inductively coupled plasma mass spectrometry to detect the arsenic content B, and the average value of the arsenic content A and the arsenic content B is taken, that is, the arsenic content in the blood meets the requirements of the test performance, while the blood detection of Comparative Examples 5-8 does not meet the performance requirements, indicating that the blood detection of the present invention can reduce the interference of other signals, and is more flexible and accurate in practical applications.
[0114] In the description of the specification, the description with reference to the terms "one embodiment", "example", "specific example", etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner.
[0115] The above contents are merely examples and explanations of the present invention. Those skilled in the art may make various modifications or additions to the specific embodiments described or replace them in a similar manner. As long as they do not deviate from the invention or exceed the scope defined by the claims, they shall all fall within the protection scope of the present invention.
Claims
1. An efficient and sensitive method for detecting arsenic content in blood. It is characterized in that The following steps are involved: S1. Mix the venous blood sample with the digestion reagent, stir, place on a heating plate for digestion, cool to room temperature, add deionized water, and obtain a blood sample to be tested; S2. Mixing the arsenic detector with deionized water and stirring to obtain a nanohybrid solution; The arsenic detector is prepared by modifying nano-ferroferric oxide with dopamine and then mixing it with composite porous cobalt oxyhydroxide nanosheets; The composite porous cobalt oxyhydroxide nanosheet is prepared by mixing a developer powder with an organic solvent, filling the mixture into a modified porous cobalt oxyhydroxide nanosheet, and then heat treating, washing, drying, and grinding. The modified porous cobalt oxyhydroxide nanosheet is prepared by reacting the porous cobalt oxyhydroxide nanosheet with a mercapto monomer; The mercapto monomer is selected from any one of 2,3-dimercaptosuccinic acid and ethanedithiol; S3. Add the nano-hybrid solution to the blood sample to be tested, stir to obtain a mixed solution, place the mixed solution on a multifunctional detection platform, record the absorbance and fluorescence intensity, and obtain the arsenic content A based on the linear equation relationship between the fluorescence intensity and absorbance and the arsenic concentration; S4. After filtering the mixed solution, place it in an analytical solution for analysis, take the supernatant and detect the arsenic content B by inductively coupled plasma mass spectrometry, and take the average value of the arsenic content A and the arsenic content B, which is the arsenic content in the blood.
2. A method for highly efficient and sensitive detection of arsenic content in blood according to claim 1, It is characterized in that The digestion reagent is prepared by mixing a nitric acid solution and a hydrogen peroxide solution in a volume ratio of 6-10:1-3.
3. A method for highly efficient and sensitive detection of arsenic content in blood according to claim 2, It is characterized in that The nitric acid concentration is 0.5-0.7 mol / L, and the hydrogen peroxide concentration is 0.29-0.32 mol / L.
4. A method for highly efficient and sensitive detection of arsenic content in blood according to claim 1, It is characterized in that The digestion temperature is 80-100° C., and the digestion time is 2-5 hours.
5. A highly efficient and sensitive method for detecting arsenic content in blood according to claim 1, It is characterized in that The developer powder is prepared by mixing acridine orange and o-phenylenediamine in a mass ratio of 10-14:3-7; the porous cobalt oxyhydroxy nanosheet has a particle size of 400-500 nm and a pore size of 50-80 nm.
6. A method for highly efficient and sensitive detection of arsenic content in blood according to claim 1, It is characterized in that The multifunctional detection platform has a wavelength of 460-470 nm in ultraviolet mode, a wavelength of 480-500 nm in fluorescence mode, and an emission wavelength of 520-530 nm.
7. A highly efficient and sensitive method for detecting arsenic content in blood according to claim 1, It is characterized in that The linear equation of the fluorescence intensity and the arsenic concentration is fluorescence intensity=21416×arsenic concentration+6185.6; the linear equation of the absorbance and the arsenic concentration is 0.0039×arsenic concentration-0.0017.
8. A method for highly efficient and sensitive detection of arsenic content in blood according to claim 1, It is characterized in that The analytical solution is prepared by mixing a sodium thiosulfate solution and a potassium iodide solution in a volume ratio of 8-12:5-8.
9. A highly efficient and sensitive method for detecting arsenic content in blood according to claim 8, It is characterized in that The concentration of the sodium thiosulfate solution is 0.1-0.3 mol / L, and the concentration of the potassium iodide solution is 0.03-0.05 mol / L.
